CClinicalTrials.gg
CompletedNCT06683430Updated Nov 12, 2024

High Potassium Diet with Spices and Herbs As Salt Substitute for Lowering Blood Pressure in Older Adults: Study Protocol

An interventional study of High Potassium, Low Sodium Diet and Standard Diet in Hypertension and Older Adults Institutionalized in Residential Homes, sponsored by Universitas Airlangga. Completed at 1 site in Angola. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Universitas Airlangga · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled May 2022, registered Nov 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This clinical trial aims to evaluate the High Potassium Diet Rich in Spices and Herbs-Salt Substitution (HPSH-SS) for reducing blood pressure in older adults. The study has two phases: the first focuses on developing a high-potassium, low-sodium diet, while the second involves a 14-day randomized controlled trial. Participants are divided into two groups: the intervention group (IG) receives an 1800 kcal daily diet with 3500 mg potassium and 1500 mg sodium, while the control group (CG) receives a diet with 1500 mg potassium and 2000 mg sodium. Key outcomes include changes in blood pressure, serum potassium, aldosterone, nitric oxide, and oxidative stress markers. The results could provide new dietary strategies for managing blood pressure in the elderly.

02

Conditions studied

  • Hypertension
  • Older Adults Institutionalized in Residential Homes

Browse trials for

Keywords

  • sodium
  • potassium
  • spices and herbs
  • blood pressure
  • hypertension
  • elderly
  • protocol study
  • gerontology
  • dietary
  • anti-hypertensive
  • oxidative stress
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 62 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Universitas Airlangga is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • older adults aged ≥60 years residing in the nursing
  • active and not bedridden
  • without infectious disease, taste disorders, or dementia
  • have blood pressure measurements indicating a systolic blood pressure (SBP) ≥130 mmHg and/or diastolic blood pressure (DBP) ≥85 mmHg

Exclusion criteria

Exclusion Criteria:

  • individuals with impaired kidney function (creatinine serum levels >1.2 mmol/L)
  • uncontrolled diabetes mellitus (fasting blood sugar >126 mg/dL)
  • obesity (BMI ≥30 kg/m2 )
  • active smokers
  • have memory impairment and depressive conditions
  • participants declining continued participation, requiring intensive hospital care, or experiencing persistent vomiting and diarrhea were excluded from the intervention.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    Intervention Group High Potassium, Low Sodium Diet

    Participants received a diet enriched with potassium (3500 mg K) and reduced sodium (1500 mg Na) for 14 days.

    Dietary Supplement: High Potassium, Low Sodium Diet

  • Placebo comparator
    Control Group Standard Diet (Low Potassium)

    Participants received a standard diet with low potassium (1700 mg K) and high sodium (2000 mg Na) daily for 14 days.

    Dietary Supplement: Standard Diet

Interventions

  • Dietary supplementHigh Potassium, Low Sodium Diet

    Daily intake of 3500 mg K and 1500 mg Na for 14 days.

  • Dietary supplementStandard Diet

    Daily intake of 1700 mg K and 2000 mg Na for 14 days.

06

What researchers measure

Primary outcomes

  1. Change in Blood Pressure (mmHg)

    Measurement of the change in systolic and diastolic blood pressure from baseline to Day 8 and Day 15 to evaluate the effect of the high-potassium, low-sodium diet intervention.

    Time frame: Baseline, Day 8, and Day 15

Secondary outcomes

  1. Change in Urinary Potassium Levels (mmol)

    All participants were provided with written and verbal instructions on the correct procedure for 24-hour urine collection to measure Na and K levels. Nurses were also instructed to assist participants with this process. Participants were asked to ensure accurate 24-hour urine collection and report any missing or uncollected urine. The urine samples were then transported by researchers to an internationally certified ISO 9001 labor laboratory for analysis of Na and K levels using the ion-selective electrode (ISE) method, which specifically responds to anions and cations. Urinary K levels were categorized as low (\< 25 mmol), normal (25-125 mmol), and high (\> 125 mmol).

    Time frame: Baseline, Day 15

  2. Change in Urinary Sodium Levels (mmol)

    All participants were provided with written and verbal instructions on the correct procedure for 24-hour urine collection to measure Na and K levels. Nurses were also instructed to assist participants with this process. Participants were asked to ensure accurate 24-hour urine collection and report any missing or uncollected urine. The urine samples were then transported by researchers to an internationally certified ISO 9001 labor laboratory for analysis of Na and K levels using the ion-selective electrode (ISE) method, which specifically responds to anions and cations. Urinary Na levels were categorized as low (\< 100 mmol), normal (100-260 mmol), and high (\> 260 mmol).

    Time frame: Baseline, Day 15

  3. Change in Serum Potassium Levels (mmol/L)

    Evaluation of changes in serum potassium levels as a response to dietary intake adjustments in the intervention group versus the control group. Serum potassium levels were determined through plasma blood testing using the ion-selective electrode (ISE) method. The samples were then transported by researchers to an internationally certified ISO 9001 laboratory. Plasma potassium levels were classified as follows: hypokalemia (\< 3.5 mmol/L), normal (3.5-5 mmol/L), and hyperkalemia (\> 5 mmol/L)

    Time frame: Baseline, Day 15

  4. Change in Plasma Nitric Oxide Levels (µmol/L)

    Measurement of plasma nitric oxide to assess vascular response to the dietary intervention.

    Time frame: Baseline, Day 15

  5. Change in Plasma F2-Isoprostane Levels (pmol/L)

    Analysis of changes in plasma F2-isoprostane as an oxidative stress marker to monitor the potential antioxidative effects of the dietary intervention.

    Time frame: Baseline, Day 15

  6. Change in Plasma Aldosterone Levels (pmol/L)

    Measurement of plasma aldosterone levels to assess any physiological changes associated with potassium and sodium intake adjustments.

    Time frame: Baseline, Day 15

  7. Change in Urinary Na/K Levels (mmol/L)

    The concentrations of sodium and potassium in urine were measured and expressed in millimoles per liter (mmol/L). The Na/K ratio in urine was calculated by dividing the sodium concentration by the potassium concentration. This ratio was used to evaluate the electrolyte balance in the study participants.

    Time frame: Baseline, Day 15

07

Study locations

1 site
  • government institutional setting in Surabaya, Indonesia, namely Griya Wreda Surabaya nursing home.
    Surabaya, Jawa Timur 60232, Angola
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06683430
Lead sponsor
Universitas Airlangga
Responsible party
Farapti Farapti (Lecturer, Universitas Airlangga) — Principal investigator
First posted
Nov 12, 2024
Start date
May 11, 2022
Primary completion
Jun 30, 2023
Completion
Feb 9, 2024
Last update
Nov 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion